Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 15/20 | 0.41 |
| ▸ | CTSS | P25774 | 7/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | PPARA | Q07869 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27646608 | 0.91 | CA1 (0.49) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL27646611 | 0.91 | CA1 (0.49) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL27479498 | 0.91 | CA1 (0.49) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL12493046 | 0.77 | CTSK (0.48) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL12493044 | 0.77 | CTSK (0.48) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL5196577 | 0.76 | CTSK (0.67) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL2837458 | 0.76 | CTSK (0.50) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL2837459 | 0.76 | CTSK (0.50) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL75827 | 0.76 | CTSK (0.53) | CA1CA2CA7CTSKCTSS | |
| SCHEMBL73696 | 0.76 | CTSK (0.53) | CA1CA2CA7CTSKCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101910158-A | Pyridine and pyrazine derivatives useful in the treatment of cell proliferative disorders | ASTRAZENECA AB | 2010-12-08 | — | — | CN | disclosed |